Atorvastatin effect on ulcerative colitis

Evaluation of atorvastatin effect on disease severity and quality of life in ulcerative colitis patients.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210713051878N1

Enrollment

Registered

2022-09-08

Start date

2021-08-22

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis. Ulcerative colitis, unspecified

Interventions

Intervention 1: Intervention group: 20 patients of ulcerative colitis who refer to gastrointestinal department of Bouali hopital (Tehran-Iran) will receive atorvastatin 40mg (Sobhan Darou-Rasht-Iran)

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients in remission phase of ulcerative colitis Age of between 18-65 Informed Consent

Exclusion criteria

Exclusion criteria: Pregnancy Lactation History of statin sensitivity

Design outcomes

Primary

Measure	Time frame
Calprotectin detection by Radio immune assay. Timepoint: Measurement of Calprotectin at the beginning of the study and after 2 months. Method of measurement: Stool calprotectin measurement by Radio immune assay.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRamin Abrishami

Islamic Azad University

babakba1374@gmail.com+98 21 4228 7965

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026